Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Christopher Wright has been appointed chief medical officer at AavantiBio. Wright previously served as senior vice president and chief medical officer of Cyclerion Therapeutics.
Adverum Biotechnologies has hired Anand Reddi as vice president of patient advocacy, access and digital innovation. Reddi recently served as head of digital innovation at Gilead Sciences. Adverum has also hired Bill Tan, former senior consultant for clinical operations at 89bio, to serve as vice president and clinical operations program lead.
Sean Brugger has joined Arcutis Biotherapeutics as executive director of field medical affairs. Most recently, Brugger was regional director of Alexion Pharmaceuticals.
Gabe Longoria has been named chief commercial officer of Astrea Bioseparations. Longoria was recently Horizon Discovery’s global head of commercial.
Anthony Ting has been appointed chief scientific officer of Bone Therapeutics. Prior to joining Bone, Ting was senior director of regenerative medicine at Athersys.
Andrew Hamer has been named chief medical officer of Cardiol Therapeutics. Previously, Hamer was executive director and global development-cardiometabolic at Amgen.
Chiesi USA has appointed Martin Marciniak vice president of medical affairs. Marciniak most recently served as vice president of U.S. medical affairs at GlaxoSmithKline.
Cybin has named Alexander Belser the company’s chief clinical officer and Aaron Bartlone the new chief operating officer. Belser recently served as chief clinical officer at Adelia Therapeutics, and Bartlone was most recently the president and managing director at AB Dynamix.
Kim Arvid Nielsen has taken the helm of Follicum as its CEO. Nielsen was formerly the chief medical officer of CytoVac.
Michael Nally has been named CEO of Flagship Pioneering’s machine-learning drug development startup Generate Biomedicines. Previously, Nally was the chief marketing officer of human health at Merck.
Flavius Martin, Amgen’s former vice president of oncology and inflammation discovery research, has been named vice president of research at Gilead Sciences.
Immunome has named Dennis Giesing the company’s new chief development officer. Recently, Giesing served as chief scientific officer at Taris Biomedical.
Mikael Hagstroem has been named CEO of LabVantage Solutions. Most recently, Hagstroem was CEO and president of MetricStream.
Joyce Rico has been appointed chief medical officer of MatriSys Bioscience. Rico was formerly chief medical officer of Novan Therapeutics.
Atul Dandekar has been tapped by Maze Therapeutics to serve as the company’s chief strategy officer. Prior to this new appointment, Dandekar was vice president and global franchise head for ophthalmology at Genentech and Roche.
Medable has named Sina Mossayeb as chief design officer. Mossayeb was previously the chief creative officer at Aero.
Medigene’s vice president of clinical affairs, René Goedkoop, is set to replace Kai Pinkernell as chief medical officer by the end of this month.
Rajkumar Patil, former vice president of research and development of Ora, has been appointed chief scientific officer of OKYO.
Former vice president of research at SiteOne Therapeutics, John Mulcahy, has been named CEO of the company.
Surface Ophthalmics has selected Associate Professor of Ophthalmology Preeya Gupta of the Duke University Eye Center as its new chief medical adviser.
Vividion Therapeutics has tapped Brian Koh to serve as head of translational sciences and clinical development. Koh was most recently senior director and clinical research/development of hematology/oncology at Gilead Sciences.
Giovanni Selvaggi has been named CEO of Xcovery. Selvaggi was formerly the company’s chief medical officer.